Bone disease in myeloma patients result from the exaggerated osteoclast activity and suppression of osteoblast function in the myelomatous bone marrow and is responsible for most serious complications of myeloma. The bone anabolic effects of bortezomib with 1.3 mg/m2 and 1 mg/m2 dosages have been previously reported. In this study, we for the first time examined the effect of Bortezomib 0.7 mg/m2 dose on bone metabolic parameters in six patients with relapse MM.
Citation: Jethava Y, Pena K, Yoon D, Stein C, Zangari M (2015) Bone Effect of Low Dose Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma. J Hematol Thrombo Dis 3:204. doi: 10.4172/2329-8790.1000204